PMID- 32598020
OWN - NLM
STAT- MEDLINE
DCOM- 20210915
LR  - 20210915
IS  - 2299-8306 (Electronic)
IS  - 0423-104X (Linking)
VI  - 71
IP  - 5
DP  - 2020
TI  - Low serum levels of meteorin-like/subfatin: an indicator of diabetes mellitus and 
      insulin resistance?
PG  - 397-403
LID - 10.5603/EP.a2020.0038 [doi]
AB  - INTRODUCTION: Meteorin-like (Metrnl), also known as subfatin, is a recently 
      discovered adipokine with a favourable effect on insulin sensitivity. Studies 
      have shown lower Metrnl levels in obese patients. However, data on its 
      circulating levels in type 2 diabetes mellitus (T2DM) patients are contradictory. 
      This study aims to evaluate serum Metrnl levels in T2DM patients and determine 
      the relationship between serum Metrnl levels and insulin resistance in these 
      patients. MATERIAL AND METHODS: This cross-sectional study was conducted among 
      150 participants. The study was carried out between June 2019 and December 2019 
      at the internal medicine outpatient clinic of a tertiary university hospital. The 
      participants were divided into three groups: group 1 (control group, n = 50), 
      group 2 (newly diagnosed T2DM, n = 50), and group 3 (long-standing diagnosed 
      T2DM, n = 50). An enzyme-linked immunosorbent assay (ELISA) was used to measure 
      the serum levels of Subfatin (Metrnl), and the correlations of Metrnl level with 
      anthropometric parameters, HOMA index, and biochemical measurements were 
      assessed. RESULTS: There was no statistically significant difference between the 
      gender (p = 0.468) and age (p = 0.067) characteristics of the three groups. The 
      Metrnl (subfatin) levels of the participants were as follows: control group - 
      20.05 (1.56-103.78); newly diagnosed T2DM group - 2.62 (1.25-103.78); and 
      long-standing diagnosed T2DM group - 2.01 (0.80-19.84) pg/mL. The Metrnl 
      (subfatin) levels of the participants in the control group were higher than in 
      the participants in the newly diagnosed T2DM and long-standing diagnosed T2DM 
      groups (p < 0.001). Subfatin demonstrated a negative correlation with insulin and 
      HOMA-IR in the control group and long-standing diagnosed T2DM group. CONCLUSIONS: 
      The subfatin level was found to be higher in the healthy control group than in 
      both diabetic patient groups. Subfatin level showed negative correlation with 
      both insulin level and HOMA index. There was a relationship between subfatin and 
      insulin resistance. Low levels of subfatin in the diabetic patient groups may 
      play a role in the pathogenesis of T2DM by increasing insulin resistance.
FAU - Onalan, Erhan
AU  - Onalan E
AD  - Department of Internal Medicine, Faculty of Medicine, Firat University, Elazig, 
      Turkey. drakdeniz@msn.com.
FAU - Cavli, Cundullah
AU  - Cavli C
AD  - Department of Internal Medicine, Faculty of Medicine, Firat University, Elazig, 
      Turkey.
FAU - Dogan, Yusuf
AU  - Dogan Y
AD  - Department of Internal Medicine, Faculty of Medicine, Firat University, Elazig, 
      Turkey.
FAU - Onalan, Ebru
AU  - Onalan E
AD  - Department of Medical Biology, Medical Faculty, Firat University, Elazig, Turkey.
FAU - Gozel, Nevzat
AU  - Gozel N
AD  - Department of Internal Medicine, Faculty of Medicine, Firat University, Elazig, 
      Turkey.
FAU - Buran, Ilay
AU  - Buran I
AD  - Department of Medical Biology, Medical Faculty, Firat University, Elazig, Turkey.
FAU - Yakar, Burkay
AU  - Yakar B
AD  - Deparment of Family Medicine, Faculty of Medicine, Firat University, Elazig, 
      Turkey.
FAU - Donder, Emir
AU  - Donder E
AD  - Department of Internal Medicine, Faculty of Medicine, Firat University, Elazig, 
      Turkey.
LA  - eng
PT  - Journal Article
DEP - 20200629
PL  - Poland
TA  - Endokrynol Pol
JT  - Endokrynologia Polska
JID - 0370674
RN  - 0 (Adipokines)
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Metrnl protein, human)
SB  - IM
MH  - Adipokines/*blood
MH  - Adult
MH  - Biomarkers/blood
MH  - Blood Glucose/metabolism
MH  - Case-Control Studies
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/*metabolism
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Follow-Up Studies
MH  - Glucose Intolerance/*blood
MH  - Humans
MH  - Insulin Resistance/*physiology
MH  - Male
MH  - Middle Aged
OTO - NOTNLM
OT  - insulin resistance
OT  - newly diagnosed T2D
OT  - subfatin/meteorin-like
OT  - type 2 diabetes mellitus
EDAT- 2020/07/01 06:00
MHDA- 2021/09/16 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/02/18 00:00 [received]
PHST- 2020/06/02 00:00 [accepted]
PHST- 2020/05/23 00:00 [revised]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/09/16 06:00 [medline]
PHST- 2020/06/30 06:00 [entrez]
AID - VM/OJS/J/67586 [pii]
AID - 10.5603/EP.a2020.0038 [doi]
PST - ppublish
SO  - Endokrynol Pol. 2020;71(5):397-403. doi: 10.5603/EP.a2020.0038. Epub 2020 Jun 29.